• SEPTEMBER 24, 1999

Nicholas Piramal's R&D efforts bear fruit

According to newspaper reports, Nicholas Piramal Limited is conducting advanced human trials on an anti-cancer and anti-infective drug. Patents have been filed in the US and India. The research and development (R&D) efforts have been jointly undertaken with Cytran Inc., US.

Nicholas Piramal Limited is one of the largest pharmaceutical companies in India, commanding a combined market share of 5%. The company has a strong presence in anti-bacterials, cardiovusculars, opthalmics, vitamins, biotek and antacids. It is the only Indian firm that is a part of the Massachusetts Institute of Technology's industrial liaison programme.

Indian pharmaceutical companies have been stepping up their R&D efforts in view of the Year 2005 deadline set by the WTO for the recognition of product patents in the country. Companies including Ranbaxy and Dr Reddy's have already achieved a significant measure of success in their efforts, with Cipla following closely. The companies have been developing products and also concentrating on their generic drugs business, which they expect, will continue to rake in profits due to the competitive advantages Indian firms enjoy. The success of its R&D efforts will propel Nicholas Piramal into this select group of Indian pharmaceutical companies.

Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

Equitymaster Agora Research Private Limited (Research Analyst)
103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407